A Study of RO5185426 in Patients With Metastatic Melanoma

ClinicalTrials.gov ID: NCT01248936

Public ClinicalTrials.gov record NCT01248936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.

Study identification

NCT ID: NCT01248936
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 374 participants

Conditions and interventions

Conditions

Malignant Melanoma

Interventions

RO5185426 Drug

Drug

Eligibility (public fields only)

Age range: 16 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2010 (Type not available)
Primary completion: Oct 2011 (Actual)
Completion: Oct 2011 (Actual)
Last update posted: Aug 12, 2016

2010 – 2011

United States locations

U.S. sites: 28
U.S. states: 20
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Tucson	Arizona	85724-5078	—
Not listed	Los Angeles	California	90095	—
Not listed	San Francisco	California	94115	—
Not listed	San Francisco	California	94117	—
Not listed	Santa Monica	California	90025	—
Not listed	Aurora	Colorado	80045	—
Not listed	New Haven	Connecticut	06520-8063	—
Not listed	Palm Harbor	Florida	34684	—
Not listed	Tampa	Florida	33612-9497	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Park Ridge	Illinois	60068	—
Not listed	Boston	Massachusetts	02114	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Detroit	Michigan	48201	—
Not listed	St Louis	Missouri	63110	—
Not listed	New York	New York	10016	—
Not listed	New York	New York	10029	—
Not listed	New York	New York	10032	—
Not listed	New York	New York	10065	—
Not listed	Cincinnati	Ohio	45242	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Portland	Oregon	97225	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Columbia	South Carolina	29210	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Dallas	Texas	75246	—
Not listed	Richmond	Virginia	23230	—
Not listed	Seattle	Washington	98195	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01248936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 12, 2016 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01248936 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →